Published in Arterioscler Thromb Vasc Biol on January 19, 2012
Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism (2012) 1.08
Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases. Cardiovasc Drugs Ther (2016) 0.86
Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res (2012) 0.82
Fibroblast Growth Factor Signaling in Metabolic Regulation. Front Endocrinol (Lausanne) (2016) 0.80
Lipoprotein(a): A Historical Appraisal. J Lipid Res (2016) 0.75
Inhibition of apolipoprotein(a) synthesis by farnesoid X receptor and fibroblast growth factor 15/19: a step toward selective lipoprotein(a) therapeutics. Arterioscler Thromb Vasc Biol (2012) 0.75
Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med (2017) 0.75
Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology (2006) 4.70
Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA (2011) 4.21
ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med (2011) 3.96
Adipose triglyceride lipase contributes to cancer-associated cachexia. Science (2011) 3.70
Sedation in screening colonoscopy: impact on quality indicators and complications. Am J Gastroenterol (2012) 2.97
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol (2012) 2.93
Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol (2013) 2.85
REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis. PLoS Biol (2009) 2.76
Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology (2011) 2.67
Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology (2002) 2.64
The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology (2013) 2.63
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology (2005) 2.45
von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology (2012) 2.36
Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med (2010) 2.21
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol (2012) 2.11
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2004) 2.02
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol (2009) 1.87
The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol (2011) 1.87
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol (2003) 1.85
Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology (2005) 1.84
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut (2012) 1.83
Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis (2010) 1.79
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 1.79
Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology (2013) 1.77
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology (2009) 1.72
Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm (2006) 1.72
Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. Hepatology (2013) 1.71
Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2011) 1.70
A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol (2007) 1.70
Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol (2005) 1.64
Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol (2006) 1.63
Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol (2005) 1.62
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol (2003) 1.60
Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta (2006) 1.57
24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2006) 1.54
Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver Int (2008) 1.52
Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis. Hepatology (2015) 1.49
The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Cell Metab (2014) 1.47
Oncosis represents the main type of cell death in mouse models of cholestasis. J Hepatol (2005) 1.46
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol (2003) 1.45
Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr (2015) 1.42
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol (2003) 1.41
Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. Liver Int (2013) 1.40
Patients with coronary slow flow phenomenon demonstrate normal myocardial blood flow and arterial wave reflection between acute episodes. Int J Cardiol (2008) 1.39
Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res (2008) 1.36
Nuclear receptors in liver disease. Hepatology (2011) 1.34
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol (2006) 1.30
Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol (2012) 1.30
Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol (2006) 1.27
Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med (2012) 1.27
Mechanisms of cholestasis. Clin Liver Dis (2008) 1.24
New molecular insights into the mechanisms of cholestasis. J Hepatol (2009) 1.23
Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J Lipid Res (2005) 1.22
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci (2010) 1.22
Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. Gastroenterology (2010) 1.17
Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. Surg Endosc (2013) 1.17
The keratin cytoskeleton in liver diseases. J Pathol (2004) 1.15
Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology (2004) 1.15
FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology (2003) 1.11
Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output. Hepatology (2011) 1.11
The liver in sepsis: patterns of response and injury. Curr Opin Crit Care (2013) 1.10
Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int (2005) 1.10
Hepatotoxicity of NONI juice: report of two cases. World J Gastroenterol (2005) 1.09
Validated comprehensive analytical method for quantification of coenzyme A activated compounds in biological tissues by online solid-phase extraction LC/MS/MS. Anal Chem (2008) 1.08
Factors affecting plasma lipoprotein(a) levels: role of hormones and other nongenetic factors. Semin Vasc Med (2004) 1.08
Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin Liver Dis (2010) 1.07
Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol (2009) 1.07
Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice. Gastroenterology (2011) 1.07
Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch (2011) 1.07
Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor alpha (PPARalpha) activity. Proc Natl Acad Sci U S A (2011) 1.05
Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver Int (2012) 1.05
Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology (2011) 1.05
Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int (2007) 1.05
The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett (2004) 1.04
Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol (2011) 1.04
Bile acid-induced Mallory body formation in drug-primed mouse liver. Am J Pathol (2002) 1.03
Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol (2005) 1.03
Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model. Lab Invest (2012) 1.02
Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. Biochim Biophys Acta (2010) 1.01
Noninvasive screening for liver fibrosis and portal hypertension by transient elastography--a large single center experience. Wien Klin Wochenschr (2012) 1.00
Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology (2010) 1.00
Bile acids induce arrhythmias in human atrial myocardium--implications for altered serum bile acid composition in patients with atrial fibrillation. Heart (2013) 0.99
Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. Hepatology (2014) 0.99
Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models. J Hepatol (2011) 0.98
Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. Int J Cancer (2011) 0.98
Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One (2012) 0.97
Hypoxic liver injury and cholestasis in critically ill patients. Curr Opin Crit Care (2013) 0.97
Common genetic variation in vitamin D metabolism is associated with liver stiffness. Hepatology (2012) 0.96
Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. Am J Physiol Gastrointest Liver Physiol (2005) 0.96
SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. Hepatology (2014) 0.96